ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1032

Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity

Tiffany Taylor1, Christine Anastasiou1, Stephanie Rush1, Laura Trupin2, Maria Dall'Era3, Patricia Katz1, Kamil Barbour4, Jinoos Yazdany1 and Milena Gianfrancesco1, 1University of California San Francisco, San Francisco, CA, 2UC San Francisco, San Francisco, CA, 3University of California San Francisco, Corte Madera, CA, 4Centers for Disease Control, Atlanta, GA

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, Epidemiology, Mortality, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Data indicate that minority populations are at higher risk of developing SLE and have more severe outcomes, including mortality. However, whether specific causes of death vary by race and ethnicity has largely been unexplored, particularly for Asians and Hispanics.

Methods: The California Lupus Surveillance Project identified potential SLE cases using community rheumatology and nephrology clinics, community hospitals, and integrated healthcare systems among individuals who were residents of San Francisco County, CA during January 1, 2007 – December 31, 2009. SLE cases were defined using American College of Rheumatology Classification Criteria (≥4 of the 11 revised criteria as defined in 1982 and updated in 1997) or two alternative definitions: SLE diagnosed by the patient’s treating rheumatologist plus 3 ACR criteria; or lupus-related kidney disease (World Health Organization class II-VI lupus nephritis upon biopsy or documented record of SLE diagnosis and dialysis or renal transplantation). Cases were matched to the 2007-2017 National Death Index (NDI) data, which included the underlying cause of death for each individual. Chi-squared tests were used to examine differences in underlying cause of death by race (white, Black, Asian), ethnicity (Hispanic, non-Hispanic), and sex (female, male). Age-standardized mortality ratios (SMRs) between SLE patients and the general San Francisco county population were calculated for the leading cause of death, and estimated observed versus expected deaths by sex, race, and Hispanic/Latino ethnicity.

Results: During the study time period, 812 deaths related to SLE were identified. Cardiovascular disease (CVD) was the leading cause of death among SLE patients overall (33%), and across all racial and ethnic groups. Other top causes included rheumatic disease (18%) and hematological/oncological conditions (18%) overall, and across all racial groups. Overall, CVD as the underlying cause of death was over three times higher among SLE cases than in the general population of San Francisco County (SMR=3.63) (Table 1). CVD deaths for those with SLE were nearly four times higher for Asians and over six times higher for Hispanic/Latinos. CVD deaths were also elevated for females (SMR=4.7) and males (SMR=3.5) with SLE compared with their non-SLE counterparts.

Conclusion: These findings indicate that CVD is the leading underlying cause of death among SLE patients across various racial and ethnic groups, and that SLE patients experience a disproportionate burden of CVD mortality compared with the general population.

Taylor_Abstract.jpeg”


Disclosures: T. Taylor, None; C. Anastasiou, None; S. Rush, None; L. Trupin, None; M. Dall'Era, AstraZeneca, 2, Aurinia, 2, Biogen, 2, Bristol Myers Squibb, 2, GlaxoSmithKline, 2, Pfizer, 2; P. Katz, None; K. Barbour, None; J. Yazdany, Pfizer, 2, Astra Zeneca, 5, Eli Lilly, 2, University of California, San Francisco, 3; M. Gianfrancesco, None.

To cite this abstract in AMA style:

Taylor T, Anastasiou C, Rush S, Trupin L, Dall'Era M, Katz P, Barbour K, Yazdany J, Gianfrancesco M. Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/causes-of-death-among-populations-with-systemic-lupus-erythematosus-by-race-and-ethnicity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/causes-of-death-among-populations-with-systemic-lupus-erythematosus-by-race-and-ethnicity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology